Helix Biopharma Q1 2025 Earnings Report

Helix Biopharma EPS Results

• Actual EPS: -$0.02
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Helix Biopharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Helix Biopharma Announcement Details

• Quarter: Q1 2025
• Date: 12/16/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Helix Biopharma (OTCMKTS:HBPCF) Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies.

Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe. The company’s integrated R&D infrastructure supports early‐phase clinical trials, biomarker discovery, formulation development and manufacturing scale‐up, reflecting its commitment to rigorous scientific validation and regulatory compliance.

Governed by a management team with extensive experience in oncology research, drug development and biopharmaceutical operations, Helix BioPharma continues to advance its immunotherapy pipeline toward commercialization milestones. The company actively explores strategic partnerships and licensing opportunities to broaden the geographic reach of its investigational therapies and address unmet medical needs worldwide.